RxDoctor Payments Data

David Whittiker, MD

Family Medicine · Wichita Falls, TXNPI 1568462901

Payments from drug & device makers

$1,247in general payments, 2019–2025

Across 75 payments — averaging $16.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$313
  • Pfizer$246
  • Bayer$157
  • AbbVie$150
  • Lilly USA, LLC$95
  • GSK$89
  • plus $198 from 9 others

What the payments were for

  • Food & beverage$1,22798%
  • Education$202%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,247 in reported general payments places this provider in the 65th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$182,128
Medicare patients
572
Services billed
2,217

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide208$240,252
EliquisApixaban245$205,038
OzempicSemaglutide157$184,494
MounjaroTirzepatide68$84,003
Trelegy ElliptaFluticasone/Umeclidin/Vilanter81$64,980
XareltoRivaroxaban38$43,919
JanuviaSitagliptin Phosphate41$37,574
FarxigaDapagliflozin Propanediol39$32,073
JardianceEmpagliflozin34$31,542
Tresiba Flextouch U-100Insulin Degludec39$23,624
KerendiaFinerenone28$22,530
Lantus SolostarInsulin Glargine,hum.Rec.Anlog90$15,629
Breo ElliptaFluticasone/Vilanterol24$15,495
Stiolto RespimatTiotropium Br/Olodaterol Hcl11$14,546
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog32$12,732

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$95$324,255276 claims
PfizerEliquis$246$205,038245 claims
Novo NordiskOzempic$313$184,494157 claims
GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta$89$84,876117 claims
MerckJanuvia$20$37,57441 claims
BayerKerendia$157$22,53028 claims
Astellas Pharma US IncMyrbetriq$41$9,29214 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Wichita Falls

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →